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Abstract
Background: Toxoplasmosis is a life-threatening infection in organ transplant recipients, people receiving corticosteroid or radia-
tion therapy, people with malignancies, and AIDS patients.
Objectives: The current study aimed to determine the prevalence of toxoplasmosis in patients receiving chemotherapy for malig-
nancies in the Bushehr province of southwest Iran.
Methods: Blood samples were taken from 86 patients who were continuously referred to the chemotherapy center in Bushehr
province and evaluated by ELISA to determine anti-Toxoplasma IgG and IgM antibodies. Moreover, a blood buffy coat of each sample
was assessed by polymerase chain reaction (PCR), targeting a 529 bp gene of T. gondii. PCR products of the positive samples were
sequenced to determine the genotype of the parasite.
Results: Anti-Toxoplasma IgG antibodies were detected in the sera of 21 (24.4%) cases. All of the patients were negative for anti-
Toxoplasma IgM antibodies. No statistically significant correlation was found between seropositivity to Toxoplasma and duration
of chemotherapy or having contact with cats. PCR detected a 529 bp band of T. gondii in the buffy coats of two out of 86 (2.3%) cases.
The sequence analysis demonstrated that both cases were 95% identical to type III (VEG strain) of T. gondii.
Conclusions: Findings of this study demonstrated the presence of type III T. gondii in the buffy coats of patients undergoing
chemotherapy. Given that toxoplasmosis is a life-threatening infection in immunocompromised patients, these patients should
be screened for toxoplasmosis before and during chemotherapy to prevent acute toxoplasmosis.
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1. Background
Toxoplasmosis is a zoonotic infection caused by an in-
tracellular protozoan, Toxoplasma gondii, which can infect
humans and a wide range of animals (1). The seropreva-
lence of toxoplasmosis in the human population varies de-
pending on geographical and socioeconomic conditions,
including eating habits, health-related practices, and host
susceptibility (2-4). The lowest rate of infection can be seen
in warm, dry, and cold areas, whereas the prevalence of in-
fection in tropical areas with humid and warm climates is
high (1).
Toxoplasmosis usually causes no overt signs or symp-
toms in immunocompetent individuals. In such cases,
mild flu-like illness with relatively common symptoms
such as muscle aches and tender lymph nodes may be
infrequently observed. However, toxoplasmosis is a seri-
ous opportunistic infection of immunocompromised pa-
tients, including those with different type of malignan-
cies, people receiving long-term steroid therapy or cyto-
toxic drugs, and AIDS patients (5, 6). Toxoplasma latency oc-
curs after acquired infection in which the parasite remains
in the body as a latent infection in the form of cysts in the
skeletal muscle, cardiac muscle, and/or the brain, which
are usually inactive and harmless. Reactivation occurs only
in immunodeficient patients.
Toxoplasma gondii is classified into three different
genotypes (I, II, and III) based on isoenzyme electrophore-
sis patterns and molecular differences (7). These three
clonal lineages may have differences in virulence,
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pathogenicity, and epidemiological patterns of occur-
rence. Thus, detection of Toxoplasma infection in patients
with any immunodeficiency status and determination of
the genotype of the parasite is important in the successful
management of the disease.
2. Objectives
Considering the importance of toxoplasmosis in im-
munocompromised patients, this study was carried out
to determine the seroprevalence of toxoplasmosis specif-
ically the genotype of T. gondii in people undergoing
chemotherapy in the Bushehr Province of southwest Iran,
which is located at the edge of the Persian Gulf and experi-
ences hot, humid weather during most seasons of the year.
3. Methods
3.1. Study Population and Sample Collection
Subjects of this cross-sectional study were 86 patients
who were referred from December, 2014 to July, 2015 to
the chemotherapy center in Bushehr province. Ethical ap-
proval for the study was given by the ethics committee of
the Shiraz University of Medical Sciences (ethics commit-
tee code: IR.SUMS.REC.1394.S350). Informed consent (oral)
was obtained from the participants (or their parents, in the
case of minors), and confidentiality of the participants’ in-
formation was guaranteed.
Blood samples (5 mL) were taken from each subject,
and sera were obtained from the collected blood. In ad-
dition, a buffy coat was obtained from each blood sam-
ple for subsequent molecular evaluation. Sera and buffy
coats were kept at -20°C until use. Sociodemographic infor-
mation and data related to the prevalence of toxoplasmo-
sis including patient’s residence, duration of chemother-
apy, educational level, contact with animals, and keeping
of house cats were collected through a predesigned ques-
tionnaire.
3.2. Serological Evaluation
Sera samples were tested for IgG and IgM anti-
Toxoplasma antibodies using a commercial ELISA kit
(PishtazTeb Diagnostics, Tehran, Iran) based on the manu-
facturer’s instructions.
3.3. DNA Extraction and PCR Amplification
DNA was extracted from the buffy coat of each sam-
ple, using the phenol chloroform method as previously de-
scribed (8). PCR was performed to amplify a 529 bp gene
of T. gondii, as described by Edvinsson et al. (9), using each
of two primers: TOXOF CAGGGAGGAAGACGAAAGTTG and
TOXOR CAGACACAGTGCATCTGGATT. The PCR reaction mix-
ture (25 µL) contained 1.25 units of Taq DNA polymerase,
1 µL of extracted DNA, 1.5 mM of MgCl2, 100 pmol of each
primer, 0.2 mM of dNTP and a 10x PCR buffer. The PCR pro-
gram consisted of one cycle of initial denaturation at 94°C
for 5 minutes, 35 cycles of denaturation at 94°C for 35 sec-
onds, annealing at 56°C for 1 minute, extension at 72°C for
1 minute, and a final extension at 72°C for 10 minutes. PCR
products were separated by electrophoresis in 1.5% agarose
gel and stained with ethidium bromide. The PCR product
was excised from the agarose gel and purified using a DNA
Gel Extraction Kit (Bioneer’s AccuPrep Gel Purification Kit,
Korea), based on the manufacturer’s instructions. The pu-
rified PCR product was sequenced using the same primers
used for PCR amplification. BLAST analysis was used to
compare the sequences with those of available T. gondii se-
quences in the GenBank to discover the genotype of the
parasite.
3.4. Statistical Analysis
Collected data were analyzed using statistical package
for the social sciences (SPSS) software (SPSS Inc., Chicago,
IL, USA; version 18,). The prevalence values relative to the
features of the subjects were analyzed with a chi-square or
Fisher’s exact test.
4. Results
Of the 86 patients studied, 37 (43%) were male and 49
(57%) were female. Most of the subjects were aged 40 -
60 years. Anti-Toxoplasma IgG was detected in 21 (24.4%)
out of 86 patients. None of the subjects tested had anti-
Toxoplasma IgM antibodies. Statistical analysis showed
no significant correlation between seropositivity to Toxo-
plasma and patient age (P > 0.05).
The frequency of anti-T. gondii IgG antibodies was
higher in women (12.8%) than in men (11.6%), but this dif-
ference was not statistically significant (P > 0.05). Of the
59 patients residing in urban areas, 13 of them (15.1%) were
seropositive for anti-Toxoplasma IgG antibodies, and this
prevalence rate was 9.3% for those living in rural areas. The
prevalence of anti-Toxoplasma IgG antibodies in illiterate
patients was higher than in educated people, although this
difference was not statistically significant. Table 1 shows
the sociodemographic features of the patients and their
relative seropositivity to Toxoplasma in this study.
All the patients’ buffy coat samples were tested for the
presence of T. gondii DNA by PCR. PCR detected a 529 bp
band of T. gondii in the buffy coats of two out of 86 (2.3%)
cases. Of these two cases, one was seropositive for IgG
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Table 1. Sociodemographic Features of the Patients Receiving Chemotherapy and Relative Seropositivity to T. gondii in Bushehr Province
Characteristics Frequency (No.) Percent (%) Positive for anti-Toxoplasma Antibody (IgG), No. % P Value
Age group, Y > 0.05
≤ 20 2 2.3 0
21 - 40 21 24.4 6 (7)
41 - 60 41 47.7 11 (12.8)
> 61 22 25.6 4 (4.7)
Gender > 0.05
Male 37 43 10 (11.6)
Female 49 57 11 (12.8)
Educational level > 0.05
Illiterate 41 47.7 13 (15.1)
Low literacy 13 15.1 2 (2.3)
Educated 32 37.2 6 (7)
Residence > 0.05
Urban 59 68.6 13 (15.1)
Rural 27 31.4 8 (9.3)
Contact with animals > 0.05
Yes 47 54.7 10 (12.8)
No 39 45.3 11 (11.6)
Keeping cat > 0.05
Yes 22 25.6 4 (4.7)
No 64 74.4 17 (19.8)
Treatment duration, Months > 0.05
< 3 16 18.7 4 ( 4.7)
3 - 6 28 32.5 7 (8.1)
6 - 12 32 37.2 7 (8.1)
> 12 10 11.6 3 (3.5)
and the other was seronegative. Sequence analysis demon-
strated that the cases were 95% identical to those of avail-
able sequences in GenBank for type III (VEG) of T. gondii (Fig-
ure 1).
5. Discussion
Toxoplasmosis is usually an asymptomatic infection in
adult humans, but it can be a fatal disease in immunocom-
promised patients. This disease is life threatening in or-
gan transplant recipients, people receiving corticosteroid
or radiation therapy, people with malignancies, and AIDS
patients (5). Clinical manifestations in these patients occur
due to reactivation of latent toxoplasmosis and can lead to
fatal meningoencephalitis and focal lesions in the central
nervous system, although they are less likely to cause my-
ocarditis and pneumonia (1, 5, 10).
In the present study, the prevalence of anti-T. gondii an-
tibodies in patients undergoing chemotherapy in Bushehr
province was found to be 24.4%. This means that about
one quarter of the patients receiving immunosuppressant
drugs have latent toxoplasmosis, and there is always a risk
of reactivation of Toxoplasma in these patients. Other stud-
ies that have been conducted in different parts of Iran with
different geographical conditions and on patients with dif-
ferent sociodemographic characteristics have also docu-
mented a relatively high prevalence of toxoplasmosis in
such patients (5, 11). In a systematic review and meta-
analysis study on 2,800 Iranian immunocompromised pa-
tients, the overall seroprevalences of toxoplasmosis in
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Figure 1. Alignment of a Sequence of Toxoplasma Isolated From the Buffy Coat of a Patient Undergoing Chemotherapy for Malignancies
SAK-TOXO, a sample from the patient (current study); HM569600.1 and HM569598, sequence IDs of T. gondii strain type III (from wild rats, Tehran, Iran); LN714493.1 and LN714508,
sequence IDs of T. gondii type III, VEG strain (from Saudi Arabia).
AIDS patients, patients receiving transplant organs, and
cancer patients have been reported as 50.5, 55.1, and 45.6%,
respectively (5). A study on patients with malignancies in
Ahwaz, south Iran revealed a seroprevalence rate of 45.2%
for toxoplasmosis (11).
The seroprevalence rate of toxoplasmosis in patients
undergoing chemotherapy in the current study is lower
than that of patients living in other areas of the country (5,
11). In fact, previous studies conducted on healthy people in
Bushehr Province have revealed a lower seroprevalence of
toxoplasmosis in comparison with other parts of the coun-
try. In a study in 2010 by Fouladvand et al. (12), the preva-
lence of toxoplasmosis in high school girls in Bushehr was
reported to be 11.5%. Bushehr is a tropical region located in
southwest Iran, and the temperature in this area is much
higher than in other parts of the country during most sea-
sons of the year. The climate and weather of the region
do not appear favorable to the growth and transmission of
Toxoplasma oocysts (12-14). In addition, individuals indige-
nous to this region tend to eat more seafood than beef or
lamb and cook the meat properly. As a result, these indi-
viduals are less prone to infection through consumption
of tissue cysts of T. gondii, which is considered one of the
main sources of Toxoplasma infection in Iran (13, 14).
In the current study, the relationship between res-
idence location and toxoplasmosis prevalence in stud-
ied patients was not statistically significant. In recent
years, increasing improvements have been made in the
health facilities and cultural development in rural areas of
Iran that have transformed the relatively traditional rural
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lifestyle into a relatively modern urban life. These lifestyle
changes in turn have reduced the chance of transmission
of zoonotic infections, although infection in animals is
still common (13-15).
In the present study, PCR was used to detect T. gondii
infection in the buffy coats of patients. PCR detected Toxo-
plasma DNA in the buffy coat of two cases, one seropositive
and the other seronegative. Sequences of the isolates were
most similar to type III of the T. gondii genotypes. The pres-
ence of type I T. gondii was previously reported in cases of
congenital toxoplasmosis in southwest Iran (16). In Spain,
T. gondii type II was found to be the most prevalent (52%)
genotype in immunocompromised patients (17).
A Study of Khan et al. (2005) on the cerebral spinal fluid
of HIV-positive patients revealed that a majority of these
patients were infected with type I strains of T. gondii (18). On
the other hand, genotyping analysis of T. gondii isolates in
samples collected from 88 immunocompromised patients
from European countries revealed Type III T. gondii as the
second most common genotype recovered from patients.
The authors of the study concluded that host factors are
much more involved than parasite factors in patients’ re-
sistance or susceptibility to toxoplasmosis (19).
Taken together, the findings of the current study
demonstrated T. gondii infection in about one quarter of
the patients undergoing chemotherapy in the Bushehr
province of southwestern Iran. Because toxoplasmosis is
an important life-threatening infection in immunocom-
promised patients, these patients should be screened for
toxoplasmosis before chemotherapy, as well as during
treatment for the prevention of acute toxoplasmosis.
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